An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19
This Medical Letter outlines the evidence underlying the US FDA’s emergency use authorisation of bamlanivimab, an investigational IgG1 monoclonal antibody for treatment of COVID-19, including specification of eligible patient groups and its dosage and administration.
Source:
Journal of the American Medical Association